Skip to content
10-K

Annual Report

Foghorn Therapeutics Inc. FHTX

0001628280-26-016814

← back to feed
Filed
Mar 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 58.7M sh
Shares Diluted FY 2025 · Dec 31, 2025 62.98M sh
Shares Diluted FY 2025 · Dec 31, 2024 54.9M sh
Capex FY 2025 · Dec 31, 2025 $50K
Capex FY 2025 · Dec 31, 2024 $906K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$86.1M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$100.41M
Cash And Equivalents FY 2025 · Dec 31, 2025 $80.88M
Cash And Equivalents FY 2025 · Dec 31, 2024 $55.45M
Stockholders Equity FY 2025 · Dec 31, 2025 −$108.5M
Stockholders Equity FY 2025 · Dec 31, 2024 −$45.53M
Stockholders Equity FY 2025 · Dec 31, 2023 −$77.19M
Current Liabilities FY 2025 · Dec 31, 2025 $59.74M
Current Liabilities FY 2025 · Dec 31, 2024 $66.99M
Total Liabilities FY 2025 · Dec 31, 2025 $306.6M
Total Liabilities FY 2025 · Dec 31, 2024 $329.51M
Current Assets FY 2025 · Dec 31, 2025 $163.24M
Current Assets FY 2025 · Dec 31, 2024 $249.6M
Total Assets FY 2025 · Dec 31, 2025 $198.1M
Total Assets FY 2025 · Dec 31, 2024 $283.98M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.18
Eps Diluted FY 2025 · Dec 31, 2024 −$1.58
Eps Basic FY 2025 · Dec 31, 2025 −$1.18
Eps Basic FY 2025 · Dec 31, 2024 −$1.58
Sga Expense FY 2025 · Dec 31, 2025 $27.55M
Sga Expense FY 2025 · Dec 31, 2024 $28.36M
Rd Expense FY 2025 · Dec 31, 2025 $85.47M
Rd Expense FY 2025 · Dec 31, 2024 $94.53M
Net Income FY 2025 · Dec 31, 2025 −$74.28M
Net Income FY 2025 · Dec 31, 2024 −$86.62M
Operating Income FY 2025 · Dec 31, 2025 −$86.39M
Operating Income FY 2025 · Dec 31, 2024 −$102.68M
Revenue FY 2025 · Dec 31, 2025 $30.91M
Revenue FY 2025 · Dec 31, 2024 $22.6M